DR. RICHARD M. FLEMING, PHD, MD, JD
Cardiologist, Nuclear Cardiologist
Certified in Positron Emission Tomography (PET)
Juris Prudence Doctor of Law
Researcher
Inventor
Author
Dr. Richard M. Fleming is a Nuclear and Preventive Cardiologist, born and raised in Waterloo, Iowa, USA. He attended the University of Northern Iowa and has degrees in Physics, Biology, Psychology and Chemistry. He attended the University of Iowa College of Medicine, Creighton University and the University of Texas Health Science Center in Houston. In addition to training in Cardiology he has special Certifications in Positron Emission Tomography. He was Board Certified in Internal Medicine in 1990 and Nuclear Cardiology in 1996. He developed both the Unified Theory of Vascular Disease establishing 'Inflammation” as the cause of coronary and peripheral vascular disease and the Quadratic Blood Flow Equation for Coronary Flow Reserve in the early to mid-1990s. He has published more than 50 papers in peer review medical journals, over 50 presentations at scientific conferences throughout the U.S., Europe and Asia, has authored 8 chapters in Medical Textbooks and written 3 independent books on Health Care. He has served as Faculty and a Professor at various Universities and in 2003 received a Physician of the Year award. His current work on SPECT Cardiac imaging promotes the detection of Vulnerable Inflammatory Plaques (VIPs) through reductions in radiation dosage by using principles similar to the detection of black holes and dark matter.
In 1994, Dr. Fleming presented to the American Heart Association his "theory" that cardiovascular disease was due to inflammation. What was theory in 1994 has become well known fact for decades and was highlighted in 2004, with a feature on ABC's 20/20 News.
Patent # 9566037 was issued to Dr. Fleming on February 14, 2017.
The Fleming Method patent (FMTVDM) covers ALL methods and devices able to measure metabolic and regional blood flow differences. This breakthrough made it possible to differentiate functionality of tissue, tissue types as well as non-tissue, and the measurement of treatment response using all isotopes, enhancing agents and devices capable of detecting and measuring isotopes.
Developing technology that disrupts the methods of conventional medicine is not always welcomed. Especially when that technology would half the revenue a $20 billion nuclear isotope industry. When physicians bring innovation to medicine, complaints to medical boards often follow along with court cases, which is why it's called, "Disruptive Technology."
